Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 660,000 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the sale, the chief executive officer directly owned 2,214,769 shares of the company's stock, valued at approximately $112,023,016.02. This trade represents a 22.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Andrew Dudum also recently made the following trade(s):
- On Monday, July 21st, Andrew Dudum sold 125,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $49.54, for a total transaction of $6,209,095.90.
- On Wednesday, July 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.25, for a total transaction of $2,388,583.50.
- On Wednesday, July 16th, Andrew Dudum sold 2,792 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.58, for a total transaction of $141,219.36.
- On Tuesday, June 17th, Andrew Dudum sold 65,110 shares of Hims & Hers Health stock. The stock was sold at an average price of $59.22, for a total transaction of $3,855,814.20.
- On Monday, June 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.51, for a total transaction of $2,686,146.34.
- On Monday, June 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.76, for a total transaction of $7,272,488.52.
- On Friday, May 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.25, for a total transaction of $2,768,855.50.
- On Friday, May 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.40, for a total transaction of $7,482,616.80.
Hims & Hers Health Stock Performance
NYSE HIMS traded down $2.02 during trading hours on Monday, reaching $49.93. 26,841,929 shares of the company were exchanged, compared to its average volume of 34,307,230. The stock has a market capitalization of $11.17 billion, a P/E ratio of 62.41, a P/E/G ratio of 3.29 and a beta of 2.08. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The business's 50 day simple moving average is $53.66 and its 200-day simple moving average is $45.15. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same quarter last year, the business posted $0.06 earnings per share. Hims & Hers Health's revenue was up 72.6% compared to the same quarter last year. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.
Analyst Ratings Changes
HIMS has been the subject of several analyst reports. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Bank of America increased their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Finally, Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $39.83.
Read Our Latest Analysis on Hims & Hers Health
Institutional Investors Weigh In On Hims & Hers Health
Hedge funds have recently bought and sold shares of the stock. Quaker Wealth Management LLC bought a new stake in Hims & Hers Health during the second quarter valued at approximately $29,000. Bessemer Group Inc. lifted its position in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health during the first quarter valued at approximately $30,000. UMB Bank n.a. lifted its position in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after purchasing an additional 933 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Hims & Hers Health in the 1st quarter worth approximately $41,000. 63.52% of the stock is currently owned by institutional investors.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.